Granulomatous hepatitis associated with glyburide.

Digestive diseases and sciences (1996-02-01)
D Saw, E Pitman, M Maung, P Savasatit, D Wasserman, C K Yeung

A wide variety of diseases and injuries can cause granulomatous hepatitis, and drug-induced granulomatous hepatitis is a well-described entity. Sulfonylurea derivatives, which are commonly used oral hypoglycemic agents in the treatment of non-insulin-dependent diabetes mellitus, have been implicated in liver disease. However, glyburide, a second-generation sulfonylurea and a potent hypoglycemic drug, is considered to have less hepatic side effects than chlorpropamide. It has been reportedly associated with cholestatic jaundice and hepatitis and with hypersensitivity angitis. A case of necrotizing granuloma has been reported. We present a second case of granulomatous hepatitis occurring in a patient who had been taking glyburide for approximately three years, and we review the literature for glyburide-associated hepatitis.

Product Number
Product Description

Glyburide, meets USP testing specifications
Glybenclamide, ≥99% (HPLC)
Glybenclamide, European Pharmacopoeia (EP) Reference Standard
Glyburide (Glibenclamide), Pharmaceutical Secondary Standard; Certified Reference Material
Glibenclamide for peak identification, European Pharmacopoeia (EP) Reference Standard